Johnson & Johnson
Johnson & Johnson Borrows $7.5B to Fund Its Purchase Of Momenta
S&P Global Ratings said that the company’s adjusted debt to a measure of earnings is at a 15-year high.
Johnson & Johnson to Buy Momenta for $6.5B
The deal will give J&J control of nipocalimab, an experimental therapy Momenta is developing to treat autoimmune diseases.
J&J Speeds Up Timeline for Coronavirus Vaccine
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
Johnson & Johnson to Start COVID-19 Vaccine Trials in July
The healthcare giant moved up the coronavirus human clinical trials timeline by about two months.
Moderna Gets $483M to Fund Corona Vaccine
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
J&J Found Liable for Helping Cause Opioid Crisis
In a landmark ruling, an Oklahoma judge said the firm's opioid sales practices were false and misleading, endangering the safety of Oklahomans.
J&J Buys Auris for $3B in Surgical Robotics Play
The deal is J&J's biggest move into surgical robotics, which "has been a gap for its medical device business."
J&J Gets Boost From Strong Cancer Drug Sales
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
Why You Should Bring Customers to the M&A Table
Deal-makers often don’t consider customers, according to a global branding consultancy. When they do, everybody wins.
Will New Tax Law Uproot Overseas Financial Structures?
The TCJA may force some U.S. companies to reconsider their strategy of shifting profits to affiliates in low-tax jurisdictions.
CFOs on the Move: Week Ending March 23
Johnson & Johnson, Heidrick & Struggles, Amblin Partners, Bruker, Computer Services, Rogers, Outfront Media, LGS Innovations, True Temper Sports